Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Intuitive Surgical, Inc. (ISRG) — XLV Health Care · S&P 500 Profile |直覺外科介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Intuitive Surgical, Inc. (ISRG) — Business, History & S&P 500 Profile | 直覺外科

Intuitive Surgical, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #77 · 直覺外科公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (ET) close
Financials: FY2024
MARKET CAP
$158.54B
Oct 29, 2026 close
S&P 500 WEIGHT
0.23%
Rank #77 · Oct 29, 2026
SECTOR RANK
#12
Health Care · Oct 29, 2026
S&P 500 RANK
#77
0.23% · Oct 29, 2026

SNAPSHOT

TickerISRG
CompanyIntuitive Surgical, Inc.
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#77 · 0.23% (Oct 29, 2026)
Sector rank#12 in Health Care (Oct 29, 2026)
HeadquartersSunnyvale, California
Founded1995
CEOGary S. Guthart
EmployeesApproximately 15,638 (Dec 31, 2024)
Market cap$158.54B (Oct 30, 2026)
Share price$432.01 (Oct 30, 2026 close)
SEC filingsEDGAR — CIK 0001035267

WHAT IT DOES

Intuitive Surgical builds the da Vinci and Ion robotic-assisted surgical systems and sells the instruments, accessories and services that go with them.

Instruments and accessories are a recurring revenue stream tied to procedure volumes.

The da Vinci 5 launch in 2024 began the next system upgrade cycle.

BUSINESS SEGMENTS

Instruments & AccessoriesInstruments and accessories used in robotic-assisted procedures. FY2024 revenue $5,079.0M.
Systemsda Vinci and Ion surgical systems. FY2024 revenue $1,966.0M.
ServicesService contracts, training and support. FY2024 revenue $1,307.1M.

HISTORY

YearMilestone
1995Intuitive Surgical is founded in Sunnyvale, California.
1999The da Vinci system receives FDA clearance.
2000Intuitive Surgical goes public.
2024The company launches da Vinci 5.

COMPETITIVE POSITION

  • da Vinci surgical systems
  • da Vinci instruments and accessories
  • Ion endoluminal systems
  • Service contracts and training
  • Trade-in and upgrade programs

FINANCIAL SNAPSHOT

Total revenue$10.06B (FY2025 revenue)
Operating income$2.95B (FY2025 operating income)
Net income$2.86B (FY2025 net income)
Diluted EPS$7.87 (FY2025 diluted EPS)
Source: Intuitive Surgical, Inc. Form 10-K for the year ended December 31, 2025 (revenue $10.06B; operating income $2.95B; net income $2.86B; diluted EPS $7.87).

KEY RISKS

  • System placements depend on hospital capital budgets, which tighten in downturns.
  • Competition from Medtronic, Johnson & Johnson and others is intensifying.
  • Regulatory scrutiny of robotic surgery outcomes can slow adoption.
  • Trade-in programs and the da Vinci 5 transition can pressure near-term margins.
  • Intellectual-property litigation is a recurring industry risk.

WHY IT MATTERS FOR THE S&P 500

Intuitive is the category-defining robotic surgery company: a large installed base generates recurring instruments revenue, and procedure growth compounds with each new system generation. The risk is valuation — the market already prices in years of growth — and rising competition.

SOURCES & METHODOLOGY

Financials, segments, headquartersIntuitive Surgical, Inc. Form 10-K for the year ended December 31, 2024 (revenue $8.35B; operating income $2.35B; net income $2.34B; diluted EPS $6.51).
Index weight & ranksSlickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026
Market cap$158.54B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

ISRG

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ISRG
公司直覺外科公司
GICS 板塊/行業健康護理(XLV)/醫療保健設備
標普500排名(按權重)#77 · 0.23%(Oct 29, 2026)
板塊內排名健康護理 #12(Oct 29, 2026)
總部加州森尼韋爾
成立1995 年
執行長加里·S·古薩特
員工約 15,638 人(2024 年 12 月 31 日)
市值$158.54B(Oct 30, 2026)
股價$432.01(Oct 30, 2026 收盤)
SEC 申報EDGAR — CIK 0001035267

業務概覽

直覺外科製造達芬奇與 Ion 機器人輔助手術系統,並銷售配套器械、配件與服務。

器械與配件是與手術量掛鉤的經常性收入來源。

2024 年達芬奇 5 的推出開啟下一輪系統升級週期。

業務板塊

器械與配件機器人輔助手術中使用的器械與配件。 2024 財年收入 50.79 億美元。
系統達芬奇與 Ion 手術系統。 2024 財年收入 19.66 億美元。
服務服務合約、培訓與支援。 2024 財年收入 13.07 億美元。

歷史沿革

年份里程碑
1995 年直覺外科在加州森尼韋爾成立。
1999 年達芬奇系統獲得 FDA 許可。
2000 年直覺外科上市。
2024 年公司推出達芬奇 5。

競爭地位

  • 達芬奇手術系統
  • 達芬奇器械與配件
  • Ion 腔內系統
  • 服務合約與培訓
  • 置換與升級計劃

財務快照

總收入$10.06B(FY2025 收入)
營業利潤$2.95B(FY2025 營業利潤)
淨利潤$2.86B(FY2025 淨利潤)
稀釋 EPS$7.87(FY2025 攤薄每股收益)
來源:直覺外科截至 2025 年 12 月 31 日年度之 Form 10-K(收入 100.6 億美元;營業利潤 29.5 億美元;淨利潤 28.6 億美元;攤薄每股收益 7.87 美元)。

主要風險

  • 系統裝機取決於醫院資本預算,經濟下行時會收緊。
  • Medtronic、強生等對手的競爭正在加劇。
  • 對機器人手術結果的監管審查可能放緩採用。
  • 置換計劃與達芬奇 5 過渡可能壓低短期利潤。
  • 知識產權訴訟是行業的經常性風險。

對標普500的重要性

直覺外科是定義品類的機器人手術公司:龐大的裝機量帶來經常性器械收入,手術量增長隨每一代新系統複利增長。風險在於估值——市場已計入多年的增長——以及競爭加劇。

來源與方法

財務、板塊、總部直覺外科截至 2024 年 12 月 31 日年度之 Form 10-K(收入 83.5 億美元;營業利潤 23.5 億美元;淨利潤 23.4 億美元;攤薄每股收益 6.51 美元)。
指數權重與排名Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取
市值$158.54B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

ISRG

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ISRG
Data as of Oct 29, 2026 · Financials FY2024 (10-K) · Market data Oct 2026
Previous · T-Mobile US, Inc. (TMUS) — XLC Communication Services · S&P 500 Profile |T-Mobile介紹Next · Seagate Technology Holdings plc (STX) — XLK Information Technology · S&P 500 Profile |希捷科技介紹

Entered 2026-10-30 05:28 · updated 2026-11-14 23:42 · rev 9